Drug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 interface.

The IL-6/GP130/STAT3 pathway is critical for the progression of multiple types of cancers. We report here the discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 protein-protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning approaches. Multiple drug scaffolds were simultaneously docked into hot spots of GP130 D1 domain by MLSD to compete with the key interacting residues of IL-6, followed by tethering to generate virtual hit compounds. Similarity searches of virtual hits on drug databases identified raloxifene and bazedoxifene as potential inhibitors of IL-6/GP130 interaction. In cancer cell assays both compounds bind to GP130 and demonstrated selective inhibition of IL-6 induced STAT3 phosphorylation and were significantly more potent than the previously reported natural product inhibitor MDL-A. The identified drugs represent a new class of lead compounds with piperidine, benzothiophene, and indole scaffolds to inhibit IL-6 induced homodimerization of GP130. Besides potential direct usage for clinic trials, the two compounds can also serve as lead compounds for optimization to speed the development of drugs selectively targeting the IL-6/GP130/STAT3 cancer signaling pathway.

[1]  Huameng Li.  Multiple Ligand Simultaneous Docking (MLSD) and Its Applications to Fragment Based Drug Design and Drug Repositioning , 2012 .

[2]  J. Heath,et al.  Identification of Three Distinct Receptor Binding Sites of Murine Interleukin-11* , 1999, The Journal of Biological Chemistry.

[3]  David S. Wishart,et al.  DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs , 2010, Nucleic Acids Res..

[4]  Andrew D Westwell,et al.  Protein–protein interactions as targets for small-molecule therapeutics in cancer , 2008, Expert Reviews in Molecular Medicine.

[5]  N. Neamati,et al.  Small molecule inhibitors of Stat3 signaling pathway. , 2007, Current cancer drug targets.

[6]  I. Czajka.  Raloxifene modulates interleukin-6 and tumor necrosis factor-α synthesis in vivo: results from a pilot clinical study , 2005 .

[7]  Y. Mándi,et al.  Relevance of transforming growth factor-β1, interleukin-8, and tumor necrosis factor-α polymorphisms in patients with chronic pancreatitis , 2007 .

[8]  H. Lim,et al.  Evidence for heterodimeric association of leukemia inhibitory factor (LIF) receptor and gp130 in the mouse uterus for LIF signaling during blastocyst implantation. , 2006, Reproduction.

[9]  N. Neamati,et al.  Chemical Therapeutics Discovery of a Novel Orally Active Small-Molecule gp 130 Inhibitor for the Treatment of Ovarian Cancer , 2013 .

[10]  Tingjun Hou,et al.  Drug and Drug Candidate Building Block Analysis , 2010, J. Chem. Inf. Model..

[11]  L. Hofbauer,et al.  Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts. , 2003, The Journal of clinical endocrinology and metabolism.

[12]  K. Yasukawa,et al.  IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. , 1993, Science.

[13]  Renxiao Wang,et al.  A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[14]  Jiayuh Lin,et al.  Celecoxib inhibits STAT3 phosphorylation and suppresses cell migration and colony forming ability in rhabdomyosarcoma cells. , 2011, Biochemical and biophysical research communications.

[15]  M. Lagerquist,et al.  Long‐term anti‐arthritic and anti‐osteoporotic effects of raloxifene in established experimental postmenopausal polyarthritis , 2008, Clinical and experimental immunology.

[16]  P. Lipsky.  Interleukin-6 and rheumatic diseases , 2006, Arthritis research & therapy.

[17]  Li Lin,et al.  A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells. , 2010, Neoplasia.

[18]  K. Garcia,et al.  Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex. , 2003, Science.

[19]  David Jou,et al.  Fragment-based drug design and drug repositioning using multiple ligand simultaneous docking (MLSD): identifying celecoxib and template compounds as novel inhibitors of signal transducer and activator of transcription 3 (STAT3). , 2011, Journal of medicinal chemistry.

[20]  Rachelle J Bienstock,et al.  Computational drug design targeting protein-protein interactions. , 2012, Current pharmaceutical design.

[21]  C. Thut,et al.  Leukemia inhibitory factor receptor is structurally related to the IL‐6 signal transducer, gp130. , 1991, The EMBO journal.

[22]  C. Edwards,et al.  The role of interleukin-6 in rheumatoid arthritis-associated osteoporosis , 2010, Osteoporosis International.

[23]  K. Aydın,et al.  Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis. , 2007, European cytokine network.

[24]  C. D. Jones,et al.  Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal in , 1984, Journal of medicinal chemistry.

[25]  K. Garcia,et al.  Hexameric Structure and Assembly of the Interleukin-6/IL-6 α-Receptor/gp130 Complex , 2003, Science.

[26]  R. Olsen,et al.  Identification of Direct Protein Targets of Small Molecules , 2010, ACS chemical biology.

[27]  Chenglong Li,et al.  Multiple ligand simultaneous docking: Orchestrated dancing of ligands in binding sites of protein , 2010, J. Comput. Chem..

[28]  D. Biskobing.  Update on bazedoxifene: A novel selective estrogen receptor modulator , 2007, Clinical interventions in aging.

[29]  David Baker,et al.  Convergent mechanisms for recognition of divergent cytokines by the shared signaling receptor gp130. , 2003, Molecular cell.

[30]  S. Akira,et al.  Interleukin-6 and its receptor: a paradigm for cytokines. , 1992, Science.

[31]  J. Ihle.  Cytokine receptor signalling , 1995, Nature.

[32]  Yanli Wang,et al.  PubChem: Integrated Platform of Small Molecules and Biological Activities , 2008 .

[33]  J. Darnell.  STATs and gene regulation. , 1997, Science.

[34]  Christopher L. McClendon,et al.  Reaching for high-hanging fruit in drug discovery at protein–protein interfaces , 2007, Nature.

[35]  J. Ihle.  Hematopoietic Signaling by the Cytokine Receptor Superfamily , 1995 .

[36]  S. Ōmura,et al.  Suppression of bone resorption by madindoline A, a novel nonpeptide antagonist to gp130 , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[37]  M. Lagerquist,et al.  Role of raloxifene as a potent inhibitor of experimental postmenopausal polyarthritis and osteoporosis. , 2007, Arthritis and rheumatism.